Capula Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Capula Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$248K	Sell	500 -300	-38%	-$133K	﹤0.01%	510
2026 Q1	$357K	Buy	800 +400	+100%	+$187K	﹤0.01%	594
2025 Q4	$181K	Sell	400 -1,100	-73%	-$474K	﹤0.01%	610
2025 Q3	$587K	Buy	1,500 +1,200	+400%	+$502K	﹤0.01%	426
2025 Q2	$134K	Buy	+300	New	+$138K	﹤0.01%	458
2024 Q4	–	Sell	-300	Closed	-$140K	–	619
2024 Q3	$140K	Buy	+300	New	+$144K	﹤0.01%	428
2023 Q1	–	Sell	-10,100	Closed	-$2.92M	–	943
2022 Q4	$2.92M	Sell	10,100 -40,100	-80%	-$12.2M	0.04%	320
2022 Q3	$14.5M	Buy	+50,200	New	+$14.4M	0.2%	139
2020 Q3	–	Sell	-8,900	Closed	-$2.58M	–	312
2020 Q2	$2.58M	Buy	+8,900	New	+$2.41M	0.09%	190
2020 Q1	–	Sell	-44,200	Closed	-$9.68M	–	458
2019 Q4	$9.68M	Hold	44,200	–	–	0.21%	118
2019 Q3	$7.49M	Buy	+44,200	New	+$7.82M	0.16%	129

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capula Management's VRTX Position: Q2 2026 in Review

Capula Management increased its Vertex Pharmaceuticals (VRTX) stake by 106% in Q2 2026, buying an estimated $116K and bringing the position to 509 shares worth $253K. The position accounts for ﹤0.01% of the portfolio, ranked #503.

Capula Management first reported a position in VRTX in Q3 2019 and has held it in 14 quarters since. The position peaked at $1.63M in Q3 2021. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Capula Management held 509 shares of Vertex Pharmaceuticals worth $253K as of Q2 2026.
Capula Management bought 262 Vertex Pharmaceuticals shares in Q2 2026, an estimated $116K.
Vertex Pharmaceuticals made up ﹤0.01% of Capula Management's portfolio in Q2 2026, its #503 holding.
Capula Management first reported a position in Vertex Pharmaceuticals in Q3 2019 and has held it in 14 quarters since.
Capula Management's Vertex Pharmaceuticals position peaked at $1.63M in Q3 2021.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Capula Management's 13F filing for Q2 2026, filed 14 Aug 2026.